- About Us
- Nano-Social Network
- Nano Consulting
- My Account
December 27th, 2005
Jack Uldrich: Late last week, Westaim Corp (Nasdaq: WEDX) priced the IPO of 4.5 million shares of its subsidiary, Nucryst Pharmaceuticals (Nasdaq: NCST), at $10 a share -- well below the forecast price of $12 to $14.
Although Nucryst is a legitimate nanotech company and its IPO deserves to be taken seriously, investors should proceed with great caution because they risk getting burned.
|Related News Press|
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
Harris & Harris Group Announces a Proposed Strategic Restructuring December 20th, 2016
In-cell molecular sieve from protein crystal February 14th, 2017
Cedars-Sinai, UCLA Scientists Use New ‘Blood Biopsies’ With Experimental Device to Speed Cancer Diagnosis and Predict Disease Spread: Leading-Edge Research Is Part of National Cancer Moonshot Initiative February 13th, 2017
Russia’s Nano-enabled Products Market to Witness Massive Growth February 8th, 2011
Adept Technology Announces Orders for Over $600K from Chinese Partner January 18th, 2011
Nanostart-held ItN Nanovation Receives Major Follow-on Order in Saudi Arabia November 29th, 2010
Homegrown Companies Developing Batteries for Clean Energy Storage November 2nd, 2010